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Abstract 
Background: Techniques for the accurate identification of activating mutations of BRAF in metastatic 
melanoma are of great clinical importance, due to the availability of targeted therapies for these tumours. There 
is uncertainty regarding the frequency with which BRAF status differs between primary and metastatic sites. 
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Methods: Between 2011 and 2016, 219 melanoma cases underwent BRAF testing in our institution. In 53 of 
these, paired primary and metastatic specimens were available for PCR and immunohistochemical evaluation.  
Results: 52 out of 53 cases (98%) showed concordant BRAF status between primary and metastatic site by IHC. 
In one case, a metastasis and its matched primary were positive by IHC but the metastasis was negative on PCR. 
On further investigation, PCR was positive in the primary and repeat PCR in the metastasis was positive, 
following macrodissection.  
Conclusions: Our results suggest that discordance of BRAF mutational status between primaries and metastases 
is a rare occurrence. In one case, immunohistochemistry provided strong evidence that initial PCR testing had 
provided a false negative result due to low tumour volume. Thus, in cases where tissue is is difficult to obtain 
from a metastasis or unavailble, the primary tumour can be used with confidence. 
Key Words: Melanoma, BRAF, Immunohistochemistry, Metastasis 
Introduction 
Cutaneous malignant melanoma is an invasive, neoplastic proliferation of the melanocytes of the skin.  
According to World Health Organisation data, there are approximately 232,000 cases of melanoma diagnosed 
per year; with the highest incidence rates seen in Australia and New Zealand, North America, and Northern and 
Western Europe. (1) 
 The landscape of somatic genetic mutations in melanoma is complex and variable between patients. (2) 
Gain-of-function mutations of BRAF (a signal transducer for a number of growth factor receptors) were shown 
to be of significance in a significant proportion of human cancer by Davies et al in 2002. (3, 4) Subsequent 
studies suggest that BRAF mutations are present in 40 – 60% of melanoma. (5-8) The most common mutant 
form of BRAF in human cancer is BRAF V600E, which accounts for over 90% of BRAF mutations in 
melanoma. (9) A small number of melanomas have an alternative substitution at position BRAF codon 600 (for 
example BRAF V600K). (9) 
 The emergence of effective targeted therapy against constitutively active BRAF has made the ability to 
accurately determine BRAF mutational status in melanoma critical to directing therapy. Vemurafenib and 
dabrafenib are small molecule inhibitors of mutated BRAF, which have been shown to extend life in individuals 
with stage IV metastatic melanoma. (10) However, these drugs are ineffective in cases lacking BRAF mutation. 
Survival in BRAF mutated disease is improved by addition of trametinib to inhibit the activity of MEK, a 
downstream protein in the BRAF signalling cascade. (11) 




 The current gold standard for testing BRAF mutational status in melanoma is real time polymerase 
chain reaction (RT-PCR), which indicates whether there is a mutation present in BRAF gene at the DNA level. 
(12) More recently, the development of a monoclonal antibody specific for BRAF V600E has made it feasible to 
test for mutant BRAF protein by immunohistochemistry (IHC). Multiple studies have demonstrated high 
concordance between results of testing by RT-PCR and IHC. (13, 14) RT-PCR is more widely validated, and 
may identify rare mutations (such as V600K) which are not detectable on IHC but predict response to BRAF 
inhibition. However, IHC may provide information on the strength and pattern of mutant protein expression 
which commercially available PCR assays cannot provide. Furthermore, IHC may be more accurate for small 
melanoma deposits where false negatives may occur on PCR if tumour cells relatively small percentage of the 
sampled tissue. (15) Therefore, IHC and RT-PCR may have complementary roles in the evaluation of BRAF 
mutational status in melanoma in the research setting. 
 An unresolved issue in BRAF testing is the frequency with which BRAF status of a melanoma primary 
differs from that of metastases to which it gives rise. A recent meta-analysis of studies examining non-
concordance of BRAF status between sites by various methods concluded that 'a clinically meaningful 
discrepancy rate of approximately 13.4% existed’. (16) Current European Society of Medical Oncology 
guidelines recommend that tissue from a metastatic lesion be used for BRAF testing in preference to primary 
tumour tissue when both are available. (17) Best practice where only primary tissue is available remains 
undefined, but the authors of the meta-analysis advocate a second procedure to biopsy a metastatic site under 
these circumstances. (16) 
 It is noteworthy that in previous work on BRAF status discordance between primary and metastatic 
melanoma, pooled rate of discordance was lower in studies using IHC to detect mutant protein, compared to 
those using DNA-based approaches. (16) Across seven studies using the VE1 anti-V600E BRAF antibody, the 
mean discordance was 5.6%. (18-24) By contrast, the mean discordance was 14% in DNA-based studies. (16) 
The reasons for this difference remain obscure, and could include technical issues around use of the relatively 
recently developed VE1 antibody. Our centre has significant previous experience in the application of VE1. (13) 
In view of this, we undertook the current study to investigate BRAF concordance by IHC between matched 
melanoma metastases and primary tumours to establish the rate of discordance in an Irish population. 
Methods 
Patient Selection 
We sought to include patients treated for melanoma at our institution (Cork University Hospital) between 2012 
and 2016 who fulfilled the following criteria: (1) Biopsy-proven melanoma primary; (2) Biopsy-proven 
melanoma metastasis of at least one site (regional lymph node, cutaneous metastasis, or distant visceral 




metastasis); (3) PCR sequencing to establish BRAF mutational status carried out on at least one site; and (4) 
Sufficient remaining tissue available from both primary and metastatic site to allow immunohistochemistry to be 
performed. 
Initial search of electronic patient records found 218 melanoma patients had undergone PCR testing to establish 
BRAF status. Of these, 72 had matched biopsy samples from primary and metastatic site. In nineteen cases, 
there was insufficient tissue from one or both sites to allow further testing, leaving a final cohort of 53 patients.  
PCR Sequencing 
All patients had undergone BRAF V600E PCR sequencing by cobas © 4800 BRAF V600 mutation test prior to 
inclusion in our study as clinically required. 
BRAF V600E Immunohistochemistry 
Immunohistochemistry for the BRAF V600E mutation was performed using the Roche Ventana anti-BRAF 
V600E VE1 clone antibody on the Ventana Benchmark Ultra platform slide staining system. This antibody was 
validated and optimised for use by Roche Diagnostics offsite prior to the commencement of the study. The 
process involved cell conditioning for 64 minutes (Tris based buffer), pre oxidation inhibition and primary 
antibody incubation for 16 minutes at 36.C. Ventana Optiview DAB IHC detection kit was used to detect BRAF 
V600E protein expression. The slides were counterstained with Ventana Haematoxylin and Bluing agent for 4 
minutes. 
Scoring of BRAF Immunohistochemistry 
Immunohistochemistry was reviewed by a consultant histopathologist who was blinded to the PCR result and 
immunohistochemistry result at the matched second site. Cases were regarded as positive if there was any 
evidence of cytoplasmic BRAF staining (1+, 2+, or 3+; see Figure 1). This interpretation was used by our group 
previously in the validation of BRAF IHC. (13)  
Ethical Approval 
Ethical approval for this study was granted by Cork University Hospital's Clinical Research Ethics Committee 
on 18th November 2014. The application reference number was ECM 4(nnn) 19/11/14. 
Results 
Clinicopathological Characteristics of the Cohort 
The cases included in the cohort included primaries and metastases from a wide range of sites and a number of 
histological subtypes were represented (see Table 1). Median age at first biopsy was 69 years and the median 
time from biopsy of primary to biopsy of metastasis was 9 months (range 0 to 83 months). 




Primary-Metastatic Concordance by Immunohistochemistry 
In all cases, the primary and metastatic tumours were concordant in terms of BRAF status as assessed by 
immunohistochemistry. 10 of 53 cases (19%) were positive for BRAF V600E mutant protein at the primary and 
metastatic site, while 43 were negative at both sites.  
Concordance of Immunohistochemistry and PCR Results 
BRAF V600E mutation was detected by PCR in 9 of 53 cases (19%), with one further case positive for BRAF 
V600K. The V600K mutated case was negative for mutated BRAF expression by IHC, as was expected based 
on previous studies using the VE1 antibody. One case was positive for expression of V600E by IHC while 
lacking evidence of a genetic mutation by PCR and we undertook further investigation to explain this 
unexpected finding. 
Further Characterisation of PCR/Immunohistochemistry Discordant Cases 
One case in which mutation was detected by PCR but not by immunohistochemistry exhibited the unusual 
BRAF V600K variant according to PCR results. Thus the negative IHC result could be explained in terms of the 
limits of current IHC techniques, which were previously outlined. 
 One case which was positive by IHC at both sites but in which PCR had failed to detect mutation in a 
metastatic deposit required further investigation. Firstly PCR of the primary lesion was undertaken and was 
positive for mutation. Subsequently, review of haematoxylin and eosin stained sections of the metastatic deposit 
demonstrated a low volume of tumour; the metastasis tested had a maximum dimension of 1.5mm and was 
present in a subcapsular location within a much larger lymph node. We speculated that negativity of the initial 
PCR carried out on the metastasis may have been due to technical issues related to the low volume of tumour 
compared to overall tissue volume. With this in mind, we carried out macrodissection on the metastatic sample 
to isolate the metastatic lesion from the background nodal tissue and then repeated PCR. Repeat PCR for the 
macrodissected metastatic tumour was positive for BRAF V600E mutation, strongly suggesting that the initial 
result was a false negative caused by technical issues with the PCR assay and related to the low volume of 
tumour at the site tested. 
Discussion 
The ability of clinical diagnostic laboratories to accurately and rapidly determine the presence or absence of 
BRAF mutation in metastatic melanoma is vital to ensure patients receive correct and timely therapy. Any issue 
impacting on laboratory testing of mutational status is of urgent research interest. We undertook this study to 
address one such issue; specifically the question of how frequently BRAF mutational status is discordant 
between a primary melanoma and the distant metastases to which it gives rise. 




 Previous work in this area has produced widely different results regarding the frequency of such 
discordance. Menzies et al and Manfredi et al reported that BRAF status of melanoma metastases as assessed by 
IHC were identical to that of the matched primary in all cases in series of 64 and 54 patients, respectively. (20, 
21) A very recent study by Nielsen et al included 82 patients with primary and metastatic melanoma with all but 
one case concordant. (22) The largest study to use IHC to compare BRAF status between primary melanomas 
and their metastases was Boursault et al, which included 88 patients and reported discordance in 4.5%. (18) 
While rates of discordance on IHC as high as 27.5% have been reported (23), no study including more than 50 
patients has shown discordance in more than 5% of cases. (16, 18-21) The characteristics of previous studies 
addressing this issue by means of IHC are summarised in Table 2. 
In contrast, rates of discordance of over 40% have been reported in some small studies (n <20) using 
DNA-based methods such as PCR. (26, 27) The largest PCR study included 236 patients and reported 
discordance in 11.8% of cases. (28) Other studies using DNA-based methods have reported rates between 4% 
and 47%. (18, 20, 29-36)In their recent meta-analysis, Valachis and Ullenhag found a significantly lower pooled 
rate of discordance in IHC-based studies (5%) compared to those using DNA-based methods (14.3%). (16) 
Nonetheless, the authors of that analysis conclude that the average rate of discordance across all studies is 
sufficient to indicate that there is ‘a need for biopsy and subsequent BRAF analysis of a metastatic lesion when 
treatment with kinase inhibitors is considered’, even when biopsy of the primary lesion has previously been 
undertaken. (16) 
 Our own data suggest that the rate of true discordance of BRAF status between matched primary and 
metastatic melanoma tumours is low. Even among studies which have used IHC, a discordance rate of 0% is 
somewhat unusual, although it has occurred in two previous studies (see Table 2). (20, 21) However, our 
findings must be interpreted with caution in the context of earlier reports of the occurrence of melanoma 
metastases with BRAF status different to that of the primary tumour. On the other hand, our lab has significant 
experience in the use of the VE1 antibody for detection of V600E BRAF, and in our hands there is a high level 
of agreement between IHC for BRAF V600E detection and PCR methods. (13) This makes it unlikely that the 
absence of discordant cases in our series can be explained by technical issues with the IHC protocol. 
 Valachis and Ullenhag discuss the possibility that false negatives on PCR due to low tumour volume 
may explain the higher primary/metastatic BRAF discordance which is seen with PCR as compared to IHC. 
However, a secondary analysis of their data including only studies which reported an adequate number of 
tumour cells did not give significantly different results to their main analysis, which they regard as evidence that 
low tumour cell content in some samples does not contribute significantly to discordance between sites. (16) 
Nonetheless, our series includes a case in which there was apparent discordance on PCR (BRAF mutated 
primary tumour giving rise to BRAF wild type metastasis) which was not replicated by IHC and in which 
subsequent repeat PCR on the metastasis post-macrodissection was positive. Therefore it remains credible that 




some instances of PCR discordance between sites could be due to technical issues related to laboratory methods 
employed. This complicates the interpretation of situations when two tumours from the same patient seem to 
have different BRAF status, and may be a major issue if testing of a metastatic site was to be required in all 
patients prior to initiation of targeted therapy, as has been proposed by some authors. (16) It should be noted that 
IHC with VE1 was positive at both sites in this case, demonstrating the usefulness of IHC as a complementary 
technique to PCR. 
 Our study has some limitations. Firstly, our sample size of 53 is relatively small, although only 4 larger 
IHC studies are documented in the literature (with 54, 64, 82 and 88 patients). It is possible that had more 
patients been included we would have found some instances of true discordance between primary and metastatic 
BRAF status. Secondly, we performed PCR on only one site in all cases except one, where discordance between 
PCR and IHC results was noted. Carrying out PCR on all cases would have allowed for a more complete 
molecular and immunohistochemical characterisation of our study group. However, as we have found IHC to be 
a reliable and robust method for detection of BRAF mutation, we consider this unlikely to be an issue. (13) 
Finally, the frequency of BRAF mutation positivity was low. 10 of 53 (19%) of cases showed evidence of 
BRAF V600E mutation on IHC. When one case which was positive for BRAF V600K mutation on PCR was 
considered the overall rate of activating BRAF mutation was 21%. While this is low compared to international 
estimates where approximately 40% of melanoma is typically BRAF mutated, previous work in the Irish 
population has suggested that the frequency of BRAF mutation in this group is lower, with a rate 24% reported 
in one of the largest studies. (37) However, it may be difficult to generalise our results to other populations with 
higher incidences of BRAF mutations in melanoma. 
 In conclusion, this study demonstrates that IHC for V600E BRAF expression using the VE1 antibody 
is a useful adjunct to PCR in assessing for the presence of the mutation melanoma and comparing its expression 
between primary lesion and distant metastases. While the finding of 100% concordance may not be replicated in 
future larger series or in other populations, taken in the context of previous studies our findings add further 
support to the conclusion that differences in BRAF status between primary and metastatic sites as determined by 
immunohistochemistry are significantly  less common than discordance as assessed by PCR. (18-25) Our 
description of a case of apparent PCR discordance which was subsequently shown to be due to a false negative 
at one site suggests that some of this difference in findings between methods may be due to technical difficulties 
with obtaining accurate molecular data from small tumour deposits.  
Figure Legends 
Figure 1: BRAF V600E immunohistochemistry staining: A) Weak 1+ positivity, 20x; B) Moderate 2+ 
positivity, 40x; C) Strong 3+ staining, 40x. 
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Figure 1: BRAF V600E immunohistochemistry staining: A) Weak 1+ positivity, 20x; B) Moderate 2+ 
positivity, 40x; C) Strong 3+ staining, 40x. 
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Table 2: A summary of all previous studies investigating the rate of discordance between melanoma 
primary and metastases by either polymerase chain reaction (PCR) or immunohistochemistry (IHC). 
Author Method of BRAF 
Assessment 
(IHC/PCR/PCR &IHC) 






Bourault et al, 
2014 18 
PCR & IHC 88 4.5% 4.5% 
Bradish et al, 2015 
28 
PCR 25 16% - 
Colombino et al, 
2013 27 
PCR 236 11.8% - 
Eriksson et al, 
2015 19 
IHC 63 - 3% 
Heinzerling et al, 
2013 29 
PCR 53 18.9% - 
Houben et al, 
2004 30 
PCR 24 17% - 
Kaji et al, 2017 25 PCR 17 47% - 
Manfredi et al, 
2016 20 
PCR & IHC 35 6% 0% 
Menzies et al, 
2014 
21 
IHC 64 - 0% 
Nardin et al, 
201531 
PCR 25 8% - 
Omholt et al, 
200332 
PCR 51 4% - 
Riveiro-
Falkenbach et al, 
201533 
PCR 140 16% - 
Saint-Jean et al, 
201434 
PCR 30 7% - 
Shinozaki et al, 
200435 
PCR 13 38% - 
Saroufim et al, 
2014 
22 
IHC 40 - 27.5% 
Verlinden et al, 
2014 
23 
IHC 30 - 7% 
Yancovitz et al, 
2012 26 
PCR 18 44% - 
Yaman et al, 2016 
24 
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